Company Founded
Arium Biolabs was established to commercialize decades of enzyme research and create novel enzyme-based technologies for therapeutics and industry.
Allostery Discovery Platform v1
First-generation allosteric-site platform deployed, integrating a biophysical enzyme engine.
Initiation of IP Portfolio
Arium files an application for first patent on allosteric-site identification.
Enzyme Discovery Platform v1
First-generation computational enzyme-design engine deployed, integrating high-throughput computational screening workflows to accelerate discovery and reduce cost.
Expansion of IP Portfolio
Arium files patents covering chemical libraries for allosteric modulators, positive allosteric-modulators design and a novel approach to enzyme design and engineering.
Pilot Biotherapeutic Program
Initiated early exploratory programs applying our proprietary enzyme design platform to high-value therapeutic targets.
SBIR Funding Application
Arium Biolabs makes its first application for NIH SBIR funding for its novel allosteric-modulator discovery technology.
IP Secured
USPTO awards the first patent on allosteric-site discovery.
Next-Gen Discovery Engine
Launched an advanced iteration of our computational platform integrating deep-learning models for structure–function prediction.
Additional IP Secured
USPTO awards a patent on chemical libraries for allosteric modulator discovery.
Novel Fentanyl Therapy Design
Arium initiates a unique approach for developing a highly effective therapy to treat the fentanyl crisis. Files for NIH SBIR funding.
IP Portfolio Expansion
USPTO awards patents on positive allosteric modulator discovery and our novel enzyme design approach.